Cargando…

Gut microbiome and CAR-T therapy

Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly being evaluated in a variety of tumors in the relapsed/refractory as well as frontline disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abid, Muhammad Bilal, Shah, Nirav N., Maatman, Theresa C., Hari, Parameswaran N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862813/ https://www.ncbi.nlm.nih.gov/pubmed/31827982 http://dx.doi.org/10.1186/s40164-019-0155-8

Ejemplares similares

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
por: Mohan, Meera, et al.
Publicado: (2021)

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
por: Zurko, Joanna, et al.
Publicado: (2021)

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses
por: Meir, Juliet, et al.
Publicado: (2021)

Could the menagerie of the gut microbiome really cure cancer? Hope or hype
por: Abid, Muhammad Bilal
Publicado: (2019)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential
por: Hussain, Ikram, et al.
Publicado: (2021)

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen
por: Palmen, Breanna, et al.
Publicado: (2023)

CAR-T Cell Therapy and the Gut Microbiota
por: Asokan, Sahana, et al.
Publicado: (2023)

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
por: Abid, Muhammad Bilal
Publicado: (2022)

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
por: Knight, Jennifer M., et al.
Publicado: (2022)

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023)

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
por: Kenkel, Troy J., et al.
Publicado: (2023)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen
por: Uyemura, Bradley S., et al.
Publicado: (2022)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
por: Hu, Yongxian, et al.
Publicado: (2022)

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
por: Abid, Muhammad Bilal, et al.
Publicado: (2022)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

The gut microbiome: Relationships with disease and opportunities for therapy
por: Durack, Juliana, et al.
Publicado: (2019)

Gut microbiome-targeted therapies for Alzheimer’s disease
por: Zhang, Tao, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Sex, gut microbiome, and cardiovascular disease risk
por: Razavi, Alexander C., et al.
Publicado: (2019)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis
por: Wahlang, Banrida, et al.
Publicado: (2021)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Gut Microbiome Toxicity: Connecting the Environment and Gut Microbiome-Associated Diseases
por: Tu, Pengcheng, et al.
Publicado: (2020)

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes
por: Knight, Jennifer M., et al.
Publicado: (2022)

Prebiotic properties of jiaogulan in the context of gut microbiome
por: Huang, Gouxin, et al.
Publicado: (2022)

Edible Plants and Their Influence on the Gut Microbiome and Acne
por: Clark, Ashley K., et al.
Publicado: (2017)

The gut microbiome and epilepsy
por: Dahlin, Maria, et al.
Publicado: (2019)

The Gut Microbiome in Neuromyelitis Optica
por: Zamvil, Scott S., et al.
Publicado: (2017)

The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response
por: Sánchez-Alcoholado, Lidia, et al.
Publicado: (2020)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Hidden Role of Gut Microbiome Dysbiosis in Schizophrenia: Antipsychotics or Psychobiotics as Therapeutics?
por: Munawar, Nayla, et al.
Publicado: (2021)

Young at Gut—Turning Back the Clock with the Gut Microbiome
por: Narasimhan, Harish, et al.
Publicado: (2021)

Gut-brain axis: altered microbiome and depression – review
por: Mohan, Anmol, et al.
Publicado: (2023)

Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
por: Gabrielli, Giulia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ijtpejq2a98vikc6n8hsomn00f